<?xml version="1.0" encoding="UTF-8"?>
<p>Several pro‐resolution molecules have been shown to decrease effectively inflammation and injury in models simulating pulmonary disease, including asthma, fibrosis, and infection. In the context of asthma, local or systemic administration of 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2448" xmlns:xlink="http://www.w3.org/1999/xlink">hydrogen peroxide</ext-link> (Reis et al., 
 <xref rid="bph15164-bib-0032" ref-type="ref">2015</xref>), 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=582" xmlns:xlink="http://www.w3.org/1999/xlink">angiotensin‐(1–7</ext-link>) (Magalhaes et al., 
 <xref rid="bph15164-bib-0023" ref-type="ref">2018</xref>), ANXA1(Bandeira‐Melo et al., 
 <xref rid="bph15164-bib-0006" ref-type="ref">2005</xref>), and LXA4 (Levy et al., 
 <xref rid="bph15164-bib-0020" ref-type="ref">2007</xref>) all decrease infiltration of eosinophils in the lung and, in general, changes in airway function. Similarly, mediators of resolution decrease inflammation, injury, and fibrosis in bleomycin‐induced pulmonary fibrosis (Damazo et al., 
 <xref rid="bph15164-bib-0011" ref-type="ref">2011</xref>; Rago et al., 
 <xref rid="bph15164-bib-0030" ref-type="ref">2019</xref>) and silicosis (Trentin et al., 
 <xref rid="bph15164-bib-0041" ref-type="ref">2015</xref>).
</p>
